Clinical Trial Update: Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dosing flexibility of oral testosterone undecanoate (LPCN 1021) in male hypogonadism completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism Male

Drugs mentioned

• Testosterone undecanoate (oral, LPCN 1021) (testosterone undecanoate)

Snippet

Sponsor: Lipocine Inc. | Conditions: Hypogonadism, Male | Phase 3 | Status: COMPLETED | Results posted: 2019-09-11